Medcomtech, S.A.

As of December 31, 2022, Medcomtech, S.A. has 12.92M shares outstanding.

As of December 31, 2022, Medcomtech, S.A. trades at an EV/EBITDA multiple of 4.89 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.18 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 4.89 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Medcomtech, S.A. trades at an EV/FCF ratio of 21.37, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of December 31, 2022, Medcomtech, S.A. maintains a current ratio of 1.44, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 519.57, indicating elevated leverage, while an interest coverage ratio of 0.81 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2022. Return on assets (ROA) is negative at -2.83, reflecting losses generated across the asset base. Inventory turnover of 1.09 indicates how many times Medcomtech, S.A. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended December 31, 2022, Medcomtech, S.A. posted a gross margin of 66.64, reflecting its pricing power and cost economics. The operating margin of 3.70 and net profit margin of -3.47 provide insight into operational efficiency.

As of December 31, 2022, Medcomtech, S.A. has an Altman Z-Score of 1.10, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.